Acorda To Opt Out Of FDA Meeting In Rush To Refile Its Inbrija NDA

Published: Sep 27, 2017

Sept 27 (Reuters) - Acorda Therapeutics Inc:

* Acorda Therapeutics ?announced update on refusal to file letter that it received from U.S. FDA regarding its new drug application for Inbrija?

* Says it ?has engaged in a constructive dialogue with FDA to determine most efficient path forward to resubmitting Inbrija NDA?

* Acorda Therapeutics - ?based on interactions with FDA, co believes it can resubmit without a type a meeting, and therefore will not request such a meeting?

Back to news